Simplifying Global Compliance
PTAB Invalidates Aventis Patent Following Mylan Challenge
The PTO’s Patent Trial and Appeals Board invalidated Aventis Pharma’s patent for the chemotherapy drug Jevtana (cabazitaxel), following a challenge from Mylan.
To View This Article:
Subscribe To Generic Line
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing